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“My pain is exhausting, and it’s rarely just pain. If not accompanied by diarrhoea, fatigue,
or other debilitating symptoms, it’s joined by a spiral of anxious thoughts about what the
pain means……. I was constantly at doctors’ and hospital appointments, but I was rarely
asked about my pain. Even now, unless I’m in flare up, no one asks me about my pain or
fatigue…. truthfully, those doctors and nurses don’t have time to askme about symptoms
if I’m not flaring up…….IBD clinics even when interested aren’t funded to manage those
symptoms…and healthcare professionals dismissed my symptoms as they don’t know
what to say, as they don’t understand pain in IBD, and they feel as powerless as I do……
given that pain is one of the top presenting complaints in IBD, I find it astonishing how little I
get asked about it”.
(Lucy Y, first diagnosed with Crohn’s disease 23 years ago. Reproduced with
permission).
1. Introduction
Crohn’s disease and ulcerative colitis (“inflammatory bowel disease”
[IBD]) are chronic relapsing intermittently acute conditions, charac-
terised by pathological changes in gut tissue, symptoms of diarrhoea,
blood loss, and abdominal pain, long-term complications (fistulae,
abscesses, and strictures), extra-abdominal manifestations such as
arthritis, and systemic illness. Symptoms dominate IBD disease
activity indices,39,42but theprimary target for treatment is inflammation
of the gut mucosa. This treatment has significantly improved over the
past decade, notably through the use of immunomodulator and
biologic drugs. However, the pattern, severity, impact, and prognosis
of symptoms still vary substantially from patient-to-patient.
Clinicians caring for people with IBD focus on controlling the active
bowel disease. Objective measures of disease activity, using endos-
copy and imaging or surrogates such as faecal calprotectin, provide
targets for disease-modifying drugs in trials and the clinic. However,
there is a discrepancy between measures of gut inflammation and the
extent and severity of patients’ symptoms,30 and neither are
straightforwardly related to measures of the overall impact on patients’
lives.30 Early mucosal healing defined by endoscopy is associated with
long-term improvements in symptom severity, but one-third of patients
with healed mucosa do not achieve clinical remission.76,77
In particular, abdominal pain that persists beyond flares, despite
optimal treatment of the gut disease, presents a common, disabling,
and unresolved problem,64,101 affecting patients’ quality of life (QoL)
and psychological well-being58,75 and posing challenges for
management.66,87 For clinicians, this means disease-targeted
treatment alone may not resolve the patient’s pain and pain-
related distress. The result is that chronic abdominal pain may
dominate patients’ lives—underrecognised in both specialist and
primary care settings, poorly assessed, and inadequately treated.
In this Topical Review, we consider evidence about chronic
abdominal pain in peoplewith IBD.Our aimwas to identify the extent
to which general principles of modern chronic pain management92
should have equal place in the IBD clinic and consultation alongside
the clinician’s concern for diagnosing and treating underlying gut
pathology, to ensure that pain in all patients with IBD is properly
recognised, formally assessed, and treated safely and effectively.
2.Occurrence, impact, andassessment of abdominal
pain in inflammatory bowel disease
Pain is a prominent IBD symptom.27,61,79 In large cohorts of
patients with IBD, 60% report abdominal pain,60 substantially
more than the 25% prevalence observed in general population
samples1,51; half have experienced it for more than 5 years.100
Pain contributes to the impact of IBD on QoL.47,58,60,75,99,101
Qualitative studies illustrate how pain and other symptoms
affect all aspects of the lives of people with IBD, including those
(such as proximity to a toilet) specific to gut problems.21 People
with IBD describe “vicious circles” between pain and their other
symptoms that create barriers to understanding and treatment of
pain.86 Reactions to pain vary from defeat to tolerance to
acceptance, but all have emotional impact.86 Pain is often not
included as a predictor of QoL outcomes in prospective
epidemiological research,94 but emerges as an independent
prognostic factor when it is.95
The dissociation between abdominal pain and indices of gut
inflammation highlights that pain should be a target formanagement
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in its own right.13,14 Yet, routine clinical assessment of patients with
IBD does not necessarily include pain. It is one of 5 items in a
commonly used clinical severity scale for Crohn’s disease,39 but not
part of the widely used Mayo Clinic four-item scale for ulcerative
colitis,42 and only one small part of a common measure of IBD
QoL.54 Each of these scales has its uses for disease assessment,
but pain assessments and measures of gut inflammation should
form distinct and separate components of consultations with
patients who have IBD, so that the need for additional pain
management, beyond the relief achieved by control of mucosal
inflammation, can be established, monitored, and acted upon.
One problem in achieving this is that there is no widely accepted
fully tested pain assessment for patients with IBD, and there are
challenges to developing one. In particular, it is not easy to separate
pain from other IBD experiences (eg, bowel disturbance and
psychological distress31) that together impair QoL in areas as
diverse as sleep, eating and food enjoyment, fatigue, work
capacity, and social relationships.47 Meanwhile, application of
current recommendations for chronic pain classification in ICD-11,
notably the regular use of numerical rating scales for pain intensity,
pain-related distress, and interference with activity,92 would help
reverse the neglect of this symptom in the clinic.
3. Mechanisms of abdominal pain in inflammatory
bowel disease
Reversible causes of abdominal pain in IBD include strictures,
abscesses, fistulae, and small intestinal bacterial overgrowth.
Renal or gall bladder calculi, common in patients with IBD, form
part of the differential diagnosis. Patients with IBD have a higher
risk of colorectal cancer, primary sclerosing cholangitis, and
cholangiocarcinoma. Surgery as part of IBD management, in
particular multiple operations, confers the additional risk of
postsurgical pain.
Most abdominal pain in people with IBD, however, is assumed
to be triggered through activation of nociceptors in the gut by
chemical, thermal, or mechanical stimuli.74 Disease remission,
assessed by resolution of gut inflammation or restoration of
normal bowel habit, might therefore be expected to improve or
resolve abdominal pain. However, 30% to 50% of patients with
IBD report significant pain despite disease remission,27,61,79 and
patients themselves distinguish pain concurrent with active bowel
disease from pain that persists beyond it.60
Visceral nociceptors innervate the gut sparsely; hence, deep
abdominal pain or discomfort is often diffuse and poorly
localised.15 These nociceptors, like other sensory afferents, have
cell bodies in the dorsal root ganglia and possess molecular
specificity.44 Most visceral afferents are autonomic and their roles
in nociception and pain are unknown.35 Abnormally prolonged
sensitisation of visceral afferents in the gastrointestinal tract after
acute inflammation can contribute to chronic pain.12 CNS
sensitisation is also apparent at the cellular level during acute
inflammation29 and further amplifies signalling from ascending
spinal pathways. This process is maintained by dysregulation of
descending control that emanates from the brain,26 where
structural and functional abnormalities in prefrontal and limbic
regions have been observed.6,45,89 Those brain regions are also
involved in emotional regulation and learning98 and may de-
termine the capacity for behavioural adjustments needed to
manage pain adaptively (for a given physical or social environ-
ment). The prefrontal–limbic abnormalities may explain the
increased risks of mood and anxiety disorders in patients with
IBD,33 disorders linked to persistence and severity of their pain.85
Such comprehensive models counter the long history of
“psychogenic” theories of abdominal pain.84,93 Although health-
care professionals understand clearly that psychosocial factors
contribute to the overall burden of living with IBD, less attention
has been paid to how affective and cognitive factors modulate
pain. New models highlight not only the role of cognitive,
behavioral, and environmental factors underlying pain perception
but also their interaction with visceral inflammation.50
However, the extent to which neuroanatomical changes
determine the chronicity of pain in IBD is unclear nor is it known
why or how they outlive episodes of gut inflammation to explain
pain despite disease remission in susceptible patients with IBD.
One clinical field producing insights to this problem is irritable
bowel syndrome (IBS). Irritable bowel syndrome is a functional
pain disorder that has abdominal pain as its cardinal symptom
and can coaggregate with IBD.70 Research clarifying the
complexity of visceral sensations of patients with IBS has
benefited from biopsychosocial research that draws on rapidly
advancing methods and tools for genetic, cellular (eg, visceral
nociceptors), systems-based (eg, gut and nervous system), and
behavioural (eg, avoidance, maladaptive coping, cognitive
biases, and reactivity) studies.24,71 The extent of overlap between
IBD and IBS clinical phenotypes and their gut pathophysiological
profiles remains controversial,7 but integrated explanations and
mechanisms for why abdominal pain persists in the absence of
continuing gut mucosal inflammation are likely relevant for both
conditions.66,70 Harnessing these insights to develop new or
better approaches to pain management for persons with IBD will
need not only a clearer understanding of what aspects of IBD pain
are particularly challenging to patients, but also where and why
existing treatments have failed or are limited.
4. Comorbid pain
Extra-abdominal disease is an additional source of chronic pain in
people with IBD; these pain comorbidities include back and joint
pain linked to axial and peripheral spondyloarthritis,38,95 and
conditions with higher prevalence in people with IBD such as
migraine62 and fibromyalgia.55 Such extra-abdominal pain is a
prominent predictor of reduced QoL and work productivity after
adjustment for IBD activity.38,95 Shared underlying causes of
visceral pain may complicate the picture,3 further illustrating the
multiple mechanisms involved in the pain of patients with IBD.25
The co-occurrence of pain syndromes adds to the complexities
and challenges of treating the individual patient, including
different targets for treatment of specific conditions such as
fibromyalgia and spondyloarthritis.
5. Pharmacological approaches to chronic pain in
patients with inflammatory bowel disease
Evidence continues to emerge that long-term pain outcomes are
improved by active therapeutic targeting of mucosal inflamma-
tion.91 Tofacitinib therapy, for example, significantly improved
QoL vs placebo in patients with moderate-to-severe active
ulcerative colitis, including significant relief of abdominal pain.68
However, many patients will require additional painmanagement.
The well-known problems of using analgesic medication for
long-term pain are exacerbated for patients with IBD.98 Many
analgesics have low efficacy and cause gut-related adverse
effects in patients with IBD, including, paradoxically, pain.100 The
challenge is how to adequately treat chronic abdominal pain while
avoiding the harms associated with medication use.
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5.1 Opioids
Opioids are problematic. Immediate pain relief with short-term
opioid use does not translate into improved functioning with long-
term use.23,36. Opioids can cause gastrointestinal-related ad-
verse effects, collectively called opioid-induced bowel
dysfunction and including constipation, incomplete evacuation,
bloating, and gastric reflux. Patients with IBD are at high risk for
this condition because they suffer from chronic relapsing-
remitting pain. Chronic high-dose opioid use can also induce
visceral hyperalgesia (narcotic bowel syndrome) in a small subset
of patients with IBD. This is highly intractable to treatment and a
cause of prolonged hospital admission.22,36,52
Despite these problems, prescription opioid use is higher
among patients with IBD compared with non-IBD patients57 and,
in England, for example, increased significantly from 1990
through 2013.16 An estimated 5% of patients with IBD become
heavy users of opioids within 10 years of diagnosis. IBD is an
independent risk factor for becoming a heavy opioid user,88 and
risk increases with psychiatric comorbidity such as depression or
anxiety.37
Research continues into whether currently available opioids
can be delivered, or new opioids developed, with radically less
potential for addiction and serious side effects,18 and into
strategies for limiting, reducing, and tightly monitoring opioid
use in patients with IBD.19,20 The specificity of visceral pain-
signalling neurons provides potential for developing peripherally
restricted analgesics specific for visceral pain, devoid of CNS
effects.15,18,44
Meanwhile, chronic use of currently licensed prescription
opioids is associated with poorer control of pain,11 increased
healthcare use,65 and higher mortality in patients with IBD.16
Long-term use of opioids therefore should, as far as possible, be
avoided for pain management in these patients, and alternatives
offered. National guidelines on opioid use for long-term pain
concur in recommending education for informed consent and
monitoring, commensurate with risk assessments.40 If continual
or repeated opioid-based analgesics are necessary, for example
in patients with major abdominal fistulae, they should preferably
be prescribed in settings with access to nonpharmacological
interventions and resources for managing acute and long-term
consequences of dose reduction or discontinuation.4,20
5.2 Alternatives to opioids
Alternative drugs to opioids also carry problems for this patient group.
Nonsteroidal anti-inflammatory drugs are limited by risk of disease
exacerbation.12,59,81 Results of phase 2 trials suggest a potential role
for anticonvulsants used for neuropathic pain, such as gabapentin
and pregabalin,81 known to improve rectal hypersensitivity in patients
with IBS.46,56 But while this might justify clinical trials in patients with
IBD, none have been reported, and furthermore the addictive
potential of these drugs and the additional burden on patients posed
by their side-effect profile raise questions about their application to
long-term nonmalignant abdominal pain.
Tricyclic antidepressants and selective norepinephrine reup-
take inhibitors improve abdominal pain without some of the GI
risks associated with conventional analgesics.28,32,52 A meta-
analysis of randomised controlled trials in IBS found that low-
dose tricyclic antidepressants alleviate abdominal pain,72 possi-
bly by reducing afferent signals from the gastrointestinal
tract.34,63 Again there are no trials in patients with IBD, and
treating chronic pain with these drugs carries familiar concerns
about long-term dependency, side effects, and withdrawal.
Both endocannabinoid receptors (CB1 and CB2) are found in
the gut and are potential targets for pain relief in IBD.2,78 A phase
2a clinical trial of a CB2 agonist (olorinab) is underway, including
pain as an outcome, in people with Crohn’s disease and
functional symptoms.17 However, psychotropic effects from
agonist activity at CB1 receptors remain a concern for most
prescribable preparations, and evidence of efficacy from clinical
trials of cannabis-based medicine for management of chronic
pain in noncancer conditions generally is lacking.82 There is a
need to understand the mechanism of abdominal pain relief
afforded by cannabis-based medicines in patients who report
benefit,43,73,83,96,97 and for robust investigations of efficacy and
effectiveness in persons with IBD both short- and long-term.
6. Psychological approaches
The focus of psychological interventions in IBD has mainly been
concerned with adherence to treatment and modification of
lifestyle factors, including stress-induced flares, but is now
addressing pain and symptoms, and applying skills for working
around IBD pain.5,8 Direct pain reduction by psychological
methods has been demonstrated,10,66,67 but requires replica-
tion in larger studies.66 Self-management skills have in principle
been endorsed by international guidelines.49 Of specific
psychological modalities, hypnotherapy has shown promise in
abdominal pain,69 although only one trial involved patients with
IBD, targeting gut activity, pain, or coping with pain: gut‐
directed hypnotherapy extended time between flares in
ulcerative colitis compared to attention controls.48 The thera-
peutic value of psychological approaches has been attributed to
anti-inflammatory effects,48,80,87 but empirical mechanistic
studies are lacking.
One source of evidence comes from studies of psychological
interventions that are concerned more generally with relieving
stress and improving quality of life in persons with IBD, factors
linked to their pain experience.85 Meta‐analysis of 21 randomised
controlled trials, however, yielded no evidence that psychological
interventions improved emotional states and QoL, or reduced
disease activity in the short‐ or long-term, in adults with IBD.90 A
narrative review echoes this conclusion.5
Nevertheless, where unhelpful beliefs about IBD and negative
biases in processing information underlie maladaptive behav-
iours, there is no a priori reason why cognitive methods (including
cognitive and behavioural methods, problem solving, and
emotional regulation53) should not be effective in relieving pain-
related distress and disability. A recent wait-list controlled study
paints a more positive efficacy profile for multicomponent
cognitive behavioural therapy, at least in decreasing effects of
IBD on QoL as well as reducing anxiety and depression in those
with lower baseline levels.9
Given the complexity of visceral pain, its strong psychological
underpinnings, and the increased impact it exerts across multiple
life domains as pain persists, additional research targeting
visceral pain in patients with IBD is called for. This will likely
require a theoretically informed, empirically derived conceptual
model that reflects the clinical realities of patients with IBD, the
trajectory of their symptoms and triggers, and is not “borrowed”
from other symptomatically similar but not necessarily mecha-
nistically similar GI diseases. A well-defined, empirically rooted
conceptual model built specifically for IBD should go a longway to
reconcile discrepant findings regarding the role of stress and the
efficacy of interventions that target stress-sensitive symptoms,
such as pain, through psychological treatments.
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7. Conclusion and future directions
Pain is a common symptom in IBD, and represents a major health
burden, significantly impacting QoL and psychological well-being.
While optimal pharmacological treatment of gut inflammation is
important for long-term control of symptoms, including pain, many
persons with IBD continue to experience long-term abdominal pain.
Chronic abdominal pain in these persons hasmultiple aetiologies and
is complex. Available treatment options are limited. Current pain
management strategies are not specific for IBD and many, notably
opioid use, are ineffective and associated with several detrimental off-
target effects. There is a clear need to develop practical patient-
focused policies for safe, rational, appropriate, and effective use of
current analgesic medications, and better alternatives for long-term
pain management.
Several priorities for future research and practice stand out. First,
develop and apply pain assessment for patients with IBD and ensure
that pain is routinely assessed as a potential influence on outcomes in
longitudinal studies. Second, integrate investigation of central and
visceral hypersensitivity and pain processing with clinical and
psychological studies as the basis for identifying and testing novel
interventions, from molecular-specific drugs to tailored behavioural
change. Third, improve the content and delivery of existing
treatments, notably psychological approaches to chronic pain, for
individuals, and the access of persons with IBD to all the options for
chronic pain management established for other long-term painful
conditions.
Many of the clinical and research issues are shared by all
chronic pain conditions. Whilst the unique challenges facing
patients with IBD and their clinicians must be recognised, it is also
vital that silos between different clinical disciplines allied to
different body viscera,41 and to relevant pain management
expertise,9,38,49 are broken down, so the many shared problems
of managing and understanding visceral and associated extra-
abdominal pain in the context of IBD can be tackled more
efficiently and effectively.
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[40] Häuser W, Schug S, Furlan AD. The opioid epidemic and national
guidelines for opioid therapy for chronic noncancer pain: a perspective
from different continents. Pain Rep 2017;12:e599.
[41] Häuser W, Baranowski A, Messelink B, Wesselmann U. Taxonomies for
chronic visceral pain. PAIN 2020;16:1129–35.
[42] Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM.
Patient defined dichotomous end points for remission and clinical
improvement in ulcerative colitis. Gut 2005;54:782–8.
[43] Hill KP. Medical marijuana for treatment of chronic pain and other
medical and psychiatric problems: a clinical review. JAMA 2015;313:
2474–83.
[44] Hockley JRF, Taylor TS, Callejo G, Wilbrey AL, Gutteridge A, Bach K,
Winchester WJ, Bulmer DC, McMurray G, Smith ESJ. Single-cell
RNAseq reveals seven classes of colonic sensory neuron. Gut 2019;68:
633–44.
[45] Hou J, Dodd K, Nair VA, Rajan S, Beniwal-Patel P, Saha S, Prabhakaran
V. Alterations in brain white matter microstructural properties in patients
with Crohn’s disease in remission. Sci Rep 2020;10:2145.
[46] Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD.
Effect of a second-generation alpha2delta ligand (pregabalin) on visceral
sensation in hypersensitive patients with irritable bowel syndrome. Gut
2007;56:1218–25.
[47] Jones JL, Nguyen GC, Benchimol EI, Bernstein CN, Bitton A, Kaplan
GG, Murthy SK, Lee K, Cooke-Lauder J, Otley AR. The impact of
inflammatory bowel disease in Canada 2018: quality of life. J Can Assoc
Gastroenterol 2019;2(Suppl 1):S42–8.
[48] Keefer L, Taft TH, Kiebles JL, Martinovich Z, Barrett TA, Palsson OS.
Gut‐directed hypnotherapy significantly augments clinical remission in
quiescent ulcerative colitis. Aliment Pharmacol Ther 2013;38:761–71.
[49] Kemp K, Dibley L, Chauhan U, Greveson K, Jäghult S, Ashton K,
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